Introduction: Identifying immune correlates of protection is a priority for malaria vaccine research. A successful pediatric Phase 2 clinical trial in Mali of FMP2.1/AS02A, a recombinant apical membrane antigen 1 (AMA1)-based vaccine candidate, provided a source of serum samples from subjects who may have developed vaccine-induced, strain-specific protective immunity to clinical malaria illness. We studied IgG subclass and avidity patterns of antibodies to the malaria protein AMA1 in a subset of participants, with the objective of identifying immune responses that may be associated with protection against malaria. We hypothesized that the AMA1 vaccine candidate would induce production of cytophilic antibody subclasses IgG1 and IgG3, as well as overall IgG avidity maturation.
Methods: Titers of IgG1, IgG2, IgG3, and IgG4, as well as avidity of antibodies to AMA1, were determined by ELISA for ten AMA1 vaccine recipients and ten control subjects who had been randomized to receive a rabies vaccine in this double-blind trial at days 0, 90, and 150 after the first of three vaccinations. To identify statistically significant differences between the groups, responses in vaccine recipients were evaluated longitudinally and compared with responses in control subjects.
Results: IgG1, IgG2, IgG3, and IgG4 were induced more strongly in vaccine recipients than in control subjects. Additionally, vaccine recipients had higher ratios of cytophilic to non-cytophilic antibodies than control subjects. Avidity indices were not significantly different between the two groups at the three time points tested, and there were no significant differences in avidity between time points in either group.
Conclusion: Contrary to our hypothesis, both cytophilic and non-cytophilic antibodies were induced by the FMP2.1/AS02A vaccine candidate and immunization did not appear to stimulate avidity maturation. Therefore, IgG1, IgG2, IgG3, and IgG4 titers are candidate variables for a humoral immune correlate of vaccine-induced protection. These results are among the first reports of the subclasses and avidity of antibodies produced in response to a malaria vaccine candidate with allele-specific protective efficacy.
|Commitee:||Jones-Lush, Lauren M., Lyke, Kirsten E., Plowe, Christopher V., Sztein, Marcelo B.|
|School:||University of Maryland, Baltimore|
|School Location:||United States -- Maryland|
|Source:||MAI 50/06M, Masters Abstracts International|
|Keywords:||Ama1, Antibody subclass, Correlate of protection, Fmp2.1/as02a, Malaria, Vaccine|
Copyright in each Dissertation and Thesis is retained by the author. All Rights Reserved
The supplemental file or files you are about to download were provided to ProQuest by the author as part of a
dissertation or thesis. The supplemental files are provided "AS IS" without warranty. ProQuest is not responsible for the
content, format or impact on the supplemental file(s) on our system. in some cases, the file type may be unknown or
may be a .exe file. We recommend caution as you open such files.
Copyright of the original materials contained in the supplemental file is retained by the author and your access to the
supplemental files is subject to the ProQuest Terms and Conditions of use.
Depending on the size of the file(s) you are downloading, the system may take some time to download them. Please be